Nothing to Sneeze at

Classic allergy desensitization techniques using a whole allergen require three to five years of treatment, during which patients often experience mild allergic reactions. Anergis S.A. believes its desensitization technology can work in a fraction of the time while also avoiding the reactions.

The company hopes to show this by using the CHF18 million ($19.6 million) it raised in a series A round last week to conduct a Phase II trial of AllerT to desensitize patients allergic to birch pollen. The round was co-led by Vinci Capital - Renaissance PME; BioMedInvest; and Sunstone. Esperante BV; Initiative Capital Romandie; private investors also participated...